References
- Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions. Arch Intern Med 2007;167:540-50
- Sabate E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization. 2003. whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed February 2012
- Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis. 7. Correlates of clinical change in an early bout. Acta Neurol Scand 1973;49:379-95
- Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
- Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
- Agashivala N, Dastani HB, Carlton R, et al. Cost-effectiveness of fingolimod in treating patients with relapsing-remitting multiple sclerosis. Am J Pharm Benefits 2011;3:320-8
- Avonex [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2011
- Rebif [package insert]. Rockland, MA: EMD Serono, Inc.; 2011
- Betaseron [package insert]. Montville, NJ; Bayer HealthCare Pharmaceuticals, Inc.; 2010
- Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009
- Copaxone [package insert]. Tel Aviv, Israel; Teva Pharmaceutical Industries Ltd.; 1998
- Tysabri [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2012
- Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012
- Abouzaid S, Wu N, Kim E, et al. Comparison of compliance to fingolimod and other first-line disease modifying treatments among patients with multiple sclerosis. Poster presented at the AMCP’s 2012 Educational Conference, October 3–5, 2012, Cincinnati, OH
- AnalySource® Web site. https://www1.analysource.com/qry/as_products.taf?_purgefilter=Y&_nc=ee630cd74f711729196667e52744f70c. Accessed August 2011
- Physician’s Fee and Coding Guide. Duluth, GA: Mag Mutual; 2010
- Consumer price index. http://www.bls.gov/cpi/. Accessed November 27, 2012
- Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
- Bell CF. The pursuit of transparency and quality improvement in cost-effectiveness analysis—a case study in disease-modifying drugs for the treatment of multiple sclerosis. J Man Care Pharm 2011;17:463-8
- Becker RV, Dembek C. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. J Man Care Pharm 2011;17:377-81
- Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
- Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomized extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-9
- Treadway K, Cutter G, Salter A, et al. Factors that influence adherence with disease modifying therapy in MS. J Neurol 2009;256:568-76